About Juvabis

The Swiss start-up company Juvabis designs next-generation aminoglycoside antibiotics that withstand mechanisms of bacterial drug-resistance and at the same time display superior tolerability due to increased target selectivity by rational design. Juvabis has been founded around a proprietary technology developed by researchers at the University of Zurich, and a pipeline of early drug candidates discovered in collaboration with researchers at the ETH Zurich and Wayne State University in Detroit.

Facts about Juvabis
  • Founding: 2017
  • Focus : Manufacturer
  • Employees: 1-10
  • Industry : Pharma

Product portfolio of Juvabis

Product portfolio

aminoglycoside antibiotics

Here you will find Juvabis AG